These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8422301)

  • 1. Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer.
    Rougier P; Chabot GG; Bonneterre J; Tigaud JM; Lucas C; Baud M; Bérille J; Gouyette A
    Eur J Cancer; 1993; 29A(2):288-9. PubMed ID: 8422301
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase Ii trial of fotemustine in advanced colorectal cancer.
    Bleiberg H; Becquart D; Michel J; Cavalli F; Gerard B
    Eur J Cancer; 1990; 26(11-12):1260-1. PubMed ID: 2150002
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer.
    Le Cesne A; Chabot G; Bérille J; Lucas C; Baud M; Gouyette A; Marty M; Le Chevalier T
    Lung Cancer; 1995 Aug; 13(1):69-78. PubMed ID: 8528641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma.
    Le Chevalier T; Zabbe C; Gouva S; Cerrina ML; Quoix E; Riviere A; Berthaud P; Prache C; Berille J
    Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1651-2. PubMed ID: 2687005
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study.
    Iliadis A; Launay-Iliadis MC; Lucas C; Fety R; Lokiec F; Tranchand B; Milano G
    Eur J Cancer; 1996 Mar; 32A(3):455-60. PubMed ID: 8814692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on Fotemustine.
    De Rossi A; Rossi L; Laudisi A; Sini V; Toppo L; Marchesi F; Tortorelli G; Leti M; Turriziani M; Aquino A; Bonmassar E; De Vecchis L; Torino F
    J Exp Clin Cancer Res; 2006 Dec; 25(4):461-8. PubMed ID: 17310834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer.
    Rudd R; Allen R; Berille J; Spiro SG; Trask C; Souhami RL
    Cancer Chemother Pharmacol; 1994; 34(5):444-6. PubMed ID: 8070014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of the clinical pharmacokinetics of fotemustine in various tumor indications].
    Lokiec F; Beerblock K; Deloffre P; Lucas C; Bizzari JP
    Bull Cancer; 1989; 76(10):1063-9. PubMed ID: 2635634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group.
    Kerbrat P; Somers R; Verweij J; Crowther D; Tursz T; Santoro A; Steward WP; Lentz MA; van Glabbeke M; Mouridsen HT
    Eur J Cancer; 1992; 29A(1):143-4. PubMed ID: 1445732
    [No Abstract]   [Full Text] [Related]  

  • 11. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
    Calabresi F; Aapro M; Becquart D; Dirix L; Wils J; Ardizzoni A; Gerard B
    Ann Oncol; 1991 May; 2(5):377-8. PubMed ID: 1954183
    [No Abstract]   [Full Text] [Related]  

  • 12. Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
    Merimsky O; Inbar M; Reider-Groswasser I; Chaitchik S
    Eur J Cancer; 1991; 27(8):1066. PubMed ID: 1832900
    [No Abstract]   [Full Text] [Related]  

  • 13. Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group).
    Rougier P; van Pottelsberghe C; Kok T; Paillot B; Wagener T; De Greve J; Fabri MC; Gerard B; Van Glabbeke M; Bleiberg H
    Eur J Cancer; 1996 Jul; 32A(8):1432-3. PubMed ID: 8869111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fotemustine: muphoran].
    Avril MF
    Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
    Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A
    Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Gill S; Shapiro J; Westerman D; Prince HM
    J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
    [No Abstract]   [Full Text] [Related]  

  • 17. [Interspecies comparison of pharmacokinetic parameters of fotemustine (nitrosourea S 10036): mice, rats, monkeys, dogs and man].
    Lucas C; Ings B; Gray AJ; Deloffre P; Lokiec F; Campbell B; Beerblock K
    Bull Cancer; 1989; 76(8):863-5. PubMed ID: 2515897
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma.
    Guaitani A; Corada M; Lucas C; Lemoine A; Garattini S; Bartosek I
    Cancer Chemother Pharmacol; 1991; 28(4):293-7. PubMed ID: 1879046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.
    Pujol JL; Monnier A; Berille J; Cerrina ML; Douillard JY; Rivière A; Grandgirard A; Gouva S; Bizzari JP; Le Chevalier T
    Br J Cancer; 1994 Jun; 69(6):1136-40. PubMed ID: 8198982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.